Rubbishing concerns that the increasing FDA scrutiny of Indian pharma companieswas a case of "irrational clampdown", Biocon CMD Kiran Mazumdar-Shaw told CNBC-TV18 that the US regulator is mandating more stringent norms for companies across the world.
Rubbishing concerns that the increasing FDA scrutiny of Indian pharma companieswas a case of "irrational clampdown", Biocon CMD Kiran Mazumdar-Shaw told CNBC-TV18 that the US regulator is mandating more stringent norms for companies across the world.
"It is raising the bar. Indian companies will have to meet them. It is a matter of time they will meeting the high standards that are being set," she said.
The FDA's frequency of audits was becoming more frequent and it was world-wide phenomenon and not restricted to Indian companies, she added.
In the interview with Latha Venkatesh and Sonia Shenoy, Shaw also outlined the company's business outlook.
Biocon stock price
On March 26, 2015, at 11:12 hrs Biocon was quoting at Rs 436.00, up Rs 2.00, or 0.46 percent. The 52-week high of the share was Rs 553.70 and the 52-week low was Rs 402.45.
The company's trailing 12-month (TTM) EPS was at Rs 20.01 per share as per the quarter ended December 2014. The stock's price-to-earnings (P/E) ratio was 21.79. The latest book value of the company is Rs 120.89 per share. At current value, the price-to-book value of the company is 3.61.
Anda sedang membaca artikel tentang
FDA India scrutiny quality issue, no witch-hunt: Biocon CMD
Dengan url
https://olahragakecantikan.blogspot.com/2015/03/fda-india-scrutiny-quality-issue-no.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
FDA India scrutiny quality issue, no witch-hunt: Biocon CMD
namun jangan lupa untuk meletakkan link
FDA India scrutiny quality issue, no witch-hunt: Biocon CMD
sebagai sumbernya
0 komentar:
Posting Komentar